AG真人官方

Smith & Nephew plc announced awards under its Global Share Plan 2020 granted on 27 August 2025 to Ajay Dhankhar. The awards are based on the London Stock Exchange closing share price of 拢13.48 measured between 6 and 19 August 2025. Performance Share awards include 40,005 shares at target vesting (vesting 8 March 2027, performance period 1 Jan 2024鈥�31 Dec 2027) and 87,370 shares shown at maximum vesting (vesting 27 August 2028, performance period 1 Jan 2025鈥�31 Dec 2028). Restricted Share awards vest in three equal tranches on 27 August 2026, 27 August 2027 and 27 August 2028, each subject to continued employment and satisfactory performance.

Smith & Nephew announced the appointment of Dr Garheng Kong as an independent Non-Executive Director and member of the Audit Committee, effective 1 September 2025. Dr Kong is managing partner and co-founder of HealthQuest Capital and holds non-executive roles including lead independent director of LabCorp and directorships at Xeris Biopharma, Lunit and IKS Health. The company notes his prior roles at Sofinnova Investments and several medtech and biopharma boards. Smith & Nephew describes itself as a global medical technology group with about 17,000 employees, operations in around 100 countries and annual sales of $5.8 billion in 2024. The filing states no UK Listing Rule disclosure obligations arise for this appointment.

Smith & Nephew plc disclosed routine share purchases made on 22 August 2025 under its Remuneration Policy to settle part of Non-Executive Directors' fees. The purchases were made net of tax and expenses and reported under the UK Market Abuse Regulation. Specific notifications include: Angie Risley acquiring 353 ordinary shares at 脗拢13.82 each; Jo Hallas acquiring 541 ordinary shares at 脗拢13.835323 each; and John Ma acquiring 202 ADRs at $37.249053 each. The announcement lists additional affected directors (Jez Maiden, Katarzyna Mazur-Hofsaess, Simon Lowth) as part of the group covered by the disclosure. The filing is a standard Form 6-K notice of insider transactions and was signed by the Company Secretary.

Smith & Nephew plc reported a notification of share purchases by a Non-Executive Director. On 20 August 2025 Sybella Stanley purchased 1,520 ordinary shares of US$0.20 each. The filing states the purchase was made in line with the company's Remuneration Policy to pay part of Non-Executive Directors' fees in shares, and that the shares were acquired net of tax and expenses. The report is a standard Section 16-style disclosure of transactions by persons discharging managerial responsibilities.

Smith & Nephew plc reported the partial vesting of awards under its Restricted Share Plan 2024. Awards granted on 16 August 2024 vest in three equal tranches on each anniversary, subject to a judgement by the Remuneration Committee. On 19 August 2025 the company received notifications that a Director had 43,839 ordinary shares vesting, of which 18,007 were sold to cover tax and 25,832 were retained. A Non-Executive Director had 2,800 shares vest. The notice discloses these transactions following the vesting event.

Smith & Nephew reported the partial vesting of conditional share awards granted under the Global Share Plan 2020. One tranche vested on 12 August 2025 from awards originally granted on 11 August 2023, which follow a three-year vesting schedule where one third vests each year.

For the disclosed individual, Rohit Kashyap (President, Advanced Wound Management and Global), 23,201 ordinary shares vested at a reported price of 拢13.571365. Of these, 5,670 shares were sold to cover taxation and 17,531 were retained. The transactions were executed on the London Stock Exchange for ISIN GB0009223206.

Smith & Nephew plc (SNN) has filed a Form 6-K dated 7 Aug 2025 disclosing an insider transaction under the UK Market Abuse Regulation.

• Executive: Elga Lohler, Chief HR Officer (classified as a PDMR).
• Action: Sale of ordinary shares.
• Volume: 12,559.65422 shares.
• Price: 拢13.407957 per share.
• Gross proceeds: 鈮� 拢168 k.
• Venue: London Stock Exchange (XLON).
• ISIN: GB0009223206.

No financial results, guidance changes or strategic announcements accompany the filing. The disclosure appears administrative, fulfilling regulatory obligations, but investors may monitor future insider activity for sentiment cues.